We have previously demonstrated that FADD can effectively target the anti-apoptotic protein cFLIP and the pro-inflammatory NF-κB pathway in various tumor cell types [35,36,118,184,185], highlighting the potential of FADD as a therapeutic candidate. The gene discussed is CFLAR; the disease is neoplasm.